Skip to main content

Wang Huimin's Form 4 filing

Edwards Lifesciences Corp (EW) · filed Feb 8, 2022

Accession no.
0001225208-22-001655
Filed
Feb 8, 2022
Trade date
Feb 8, 2022
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $699.8K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Wang HuiminCIK 0001204553Officer (CVP, Japan & Intercontinental)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 8, 2022Common StockMOption exerciseAcquired+6,350$21.76+$138,176104,376.89Direct
Feb 8, 2022Common StockSSaleDisposed−6,350$110.20−$699,77098,026.89Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 8, 2022Common StockMOption exerciseDisposed−6,350$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Read the full filing on SEC EDGAR (opens in a new tab)